News
DAWN
17.17
-2.28%
-0.40
Analysts Offer Insights on Healthcare Companies: Day One Biopharmaceuticals (DAWN), Amgen (AMGN) and Omnicell (OMCL)
TipRanks · 2d ago
Novel Pediatric Cancer Treatment Boosts Day One Biopharmaceuticals (NASDAQ:DAWN)
TipRanks · 4d ago
Weekly Report: what happened at DAWN last week (0422-0426)?
Weekly Report · 6d ago
Analysts Are Bullish on These Healthcare Stocks: Accolade (ACCD), PROCEPT BioRobotics (PRCT)
TipRanks · 04/26 12:05
These Are The Biotechs Showing Up At The Biggest Cancer Meeting Of The Year (Oral Presentations)
Annual Meeting of the American Society of Clinical Oncology will be held in Chicago. The oral presentations will cover a range of topics including targeted therapies and immunologic therapies for various types of cancer. The plenary session will feature presentations on esophageal cancer, melanoma and lung cancer.
Seeking Alpha · 04/25 21:49
Day One Biopharmaceuticals (DAWN) Shares Cross Below 200 DMA
NASDAQ · 04/25 17:20
Day One Biopharm Price Target Maintained With a $33.00/Share by Needham
Dow Jones · 04/25 09:40
Needham Reiterates Buy on Day One Biopharmaceutical, Maintains $33 Price Target
Benzinga · 04/25 09:29
Day One slips despite Ojemda approval as BofA says label “not a home run”
Day One Biopharmaceuticals received FDA approval for its lead candidate, Ojemda, on Tuesday. Bank of America says the drug's label is "not a homerun but not an overhang" The company's stock sold off a day after the drug was approved for pediatric brain cancer.
Seeking Alpha · 04/24 19:05
Day One Pharmaceuticals: Ojemda Approval A Big Win, Current Valuation Fair
Seeking Alpha · 04/24 15:20
DAY ONE BIOPHARMACEUTICALS INC <DAWN.O>: JP MORGAN RAISES TARGET PRICE TO $39 FROM $36
Reuters · 04/24 15:12
Day One Biopharmaceuticals Achieves FDA Approval and Rare Voucher
TipRanks · 04/24 12:13
Analysts Offer Insights on Healthcare Companies: Neurocrine (NBIX), Day One Biopharmaceuticals (DAWN) and Roche Holding AG (OtherRHHVF)
TipRanks · 04/24 11:50
DAY ONE BIOPHARMACEUTICALS INC <DAWN.O>: NEEDHAM RAISES TARGET PRICE TO $33 FROM $30
Reuters · 04/24 11:13
Analysts Are Bullish on These Healthcare Stocks: Oculis Holding (OCS), Day One Biopharmaceuticals (DAWN)
TipRanks · 04/24 10:21
Day One Biopharm Price Target Maintained With a $50.00/Share by HC Wainwright & Co.
Dow Jones · 04/24 10:19
HC Wainwright & Co. Reiterates Buy on Day One Biopharmaceutical, Maintains $50 Price Target
Benzinga · 04/24 10:09
Analysts Offer Insights on Healthcare Companies: Day One Biopharmaceuticals (DAWN), Biogen (BIIB) and Neurocrine (NBIX)
TipRanks · 04/24 09:42
Day One Biopharm Price Target Raised to $33.00/Share From $30.00 by Needham
Dow Jones · 04/24 09:38
Day One Biopharm Is Maintained at Buy by Needham
Dow Jones · 04/24 09:38
More
Webull provides a variety of real-time DAWN stock news. You can receive the latest news about Day One Biopharmaceuticals, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About DAWN
Day One Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing targeted therapies for people of all ages with life-threatening diseases. The Company partners with clinical oncologists, families, and scientists to identify, acquire, and develop cancer treatments. Its product candidates include tovorafenib, pimasertib and the VRK1 program. The Company’s lead product candidate, tovorafenib, is an investigational, oral, brain-penetrant, highly selective type II RAF kinase inhibitor. The Company’s pipeline also includes pimasertib, an investigational, oral, highly selective small molecule inhibitor of mitogen-activated protein kinases 1 and 2 (MEK-1/-2). It has initiated an open-label, multicenter, phase Ib/IIa umbrella master trial, or FIRELIGHT-1, of tovorafenib as a monotherapy or in combination, which consists of two substudies. Substudy 1 is a phase IIa trial of tovorafenib as a monotherapy in patients 12 years and older.